<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>DuaDeep-SeqAffinity: Dual-Stream Deep Learning Framework for Sequence-Only Antigen-Antibody Affinity Prediction - Health AI Hub</title>
    <meta name="description" content="DuaDeep-SeqAffinity introduces a novel dual-stream deep learning framework that accurately predicts antigen-antibody binding affinity solely from amino acid seq">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>DuaDeep-SeqAffinity: Dual-Stream Deep Learning Framework for Sequence-Only Antigen-Antibody Affinity Prediction</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2512.22007v1" target="_blank">2512.22007v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-12-26
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Aicha Boutorh, Soumia Bouyahiaoui, Sara Belhadj, Nour El Yakine Guendouz, Manel Kara Laouar
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.LG
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 1.00 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2512.22007v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2512.22007v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">DuaDeep-SeqAffinity introduces a novel dual-stream deep learning framework that accurately predicts antigen-antibody binding affinity solely from amino acid sequences, circumventing the need for expensive 3D structures. Leveraging pre-trained ESM-2 embeddings with a hybrid CNN-Transformer architecture, the model significantly outperforms state-of-the-art methods and even structure-sequence hybrids, demonstrating sequence data's capacity to capture crucial binding patterns. This innovation enables highly scalable and efficient high-throughput screening, accelerating therapeutic discovery.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This innovation is crucial for drug discovery and vaccine development by enabling rapid, scalable screening of potential therapeutic antibodies and antigens. It drastically cuts down the time and cost associated with traditional experimental or structure-dependent computational methods, accelerating the identification of promising candidates.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>This research applies a dual-stream deep learning framework (medical AI) to predict antigen-antibody binding affinity. This AI application accelerates critical steps in drug and vaccine design by providing a scalable, sequence-only method for high-throughput screening of potential therapeutic candidates or vaccine components, thereby streamlining the development of medical countermeasures.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>DuaDeep-SeqAffinity is a sequence-only deep learning framework designed for antigen-antibody affinity prediction, eliminating the reliance on scarce and computationally expensive 3D protein structures.</li>
                    
                    <li>The framework employs a novel dual-stream hybrid architecture that utilizes pre-trained ESM-2 protein language model embeddings as input features.</li>
                    
                    <li>One stream comprises 1D Convolutional Neural Networks (CNNs) to detect local sequence motifs, while the other leverages Transformer encoders for learning global contextual representations.</li>
                    
                    <li>A fusion module integrates the features extracted by both streams, which are then passed to a fully connected network for final affinity score regression.</li>
                    
                    <li>The model achieved a superior Pearson correlation of 0.688, an R^2 of 0.460, and a Root Mean Square Error (RMSE) of 0.737, significantly outperforming single-branch variants (ESM-CNN, ESM-Transformer) and existing state-of-the-art sequence-only methods.</li>
                    
                    <li>Notably, DuaDeep-SeqAffinity achieved an Area Under the Curve (AUC) of 0.890, which not only surpassed sequence-only benchmarks but also exceeded the performance of some structure-sequence hybrid models, indicating its strong predictive power from sequence data alone.</li>
                    
                    <li>The findings suggest that high-fidelity sequence embeddings can effectively capture essential binding patterns typically thought to require structural modeling, providing a scalable and efficient solution for high-throughput screening in drug and vaccine development.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>DuaDeep-SeqAffinity utilizes a dual-stream deep learning architecture that processes antigen and antibody amino acid sequences. It generates pre-trained embeddings using the ESM-2 protein language model. One stream employs 1D Convolutional Neural Networks (CNNs) to capture local sequence motifs, while the second stream uses Transformer encoders to extract global contextual representations. A subsequent fusion module integrates features from both streams, which are then fed into a fully connected neural network for affinity score regression.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>DuaDeep-SeqAffinity demonstrated superior performance, achieving a Pearson correlation of 0.688, an R^2 of 0.460, and an RMSE of 0.737. It significantly outperformed single-branch variants (ESM-CNN, ESM-Transformer) and existing state-of-the-art sequence-only methods. Crucially, it achieved an AUC of 0.890, surpassing even structure-sequence hybrid models, indicating its ability to extract essential binding patterns from sequences alone.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>By providing a highly efficient and scalable method for predicting antigen-antibody affinity without relying on scarce and expensive 3D structural data, DuaDeep-SeqAffinity can significantly accelerate the discovery and development of novel therapeutic antibodies, vaccines, and diagnostic tools. This enables high-throughput virtual screening of vast sequence libraries, potentially reducing lead optimization cycles and bringing new treatments to patients faster.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract does not explicitly state any limitations of the DuaDeep-SeqAffinity framework.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The abstract does not explicitly state any future research directions.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Immunology</span>
                    
                    <span class="tag">Pharmacology</span>
                    
                    <span class="tag">Drug Discovery</span>
                    
                    <span class="tag">Vaccinology</span>
                    
                    <span class="tag">Biotechnology</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Antigen-Antibody Affinity</span>
                    
                    <span class="tag tag-keyword">Deep Learning</span>
                    
                    <span class="tag tag-keyword">Sequence-Only Prediction</span>
                    
                    <span class="tag tag-keyword">Protein Language Models</span>
                    
                    <span class="tag tag-keyword">ESM-2</span>
                    
                    <span class="tag tag-keyword">Drug Discovery</span>
                    
                    <span class="tag tag-keyword">Vaccine Development</span>
                    
                    <span class="tag tag-keyword">High-throughput Screening</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Predicting the binding affinity between antigens and antibodies is fundamental to drug discovery and vaccine development. Traditional computational approaches often rely on experimentally determined 3D structures, which are scarce and computationally expensive to obtain. This paper introduces DuaDeep-SeqAffinity, a novel sequence-only deep learning framework that predicts affinity scores solely from their amino acid sequences using a dual-stream hybrid architecture. Our approach leverages pre-trained ESM-2 protein language model embeddings, combining 1D Convolutional Neural Networks (CNNs) for local motif detection with Transformer encoders for global contextual representation. A subsequent fusion module integrates these multi-faceted features, which are then passed to a fully connected network for final score regression. Experimental results demonstrate that DuaDeep-SeqAffinity significantly outperforms individual architectural components and existing state-of-the-art (SOTA) methods. DuaDeep achieved a superior Pearson correlation of 0.688, an R^2 of 0.460, and a Root Mean Square Error (RMSE) of 0.737, surpassing single-branch variants ESM-CNN and ESM-Transformer. Notably, the model achieved an Area Under the Curve (AUC) of 0.890, outperforming sequence-only benchmarks and even surpassing structure-sequence hybrid models. These findings prove that high-fidelity sequence embeddings can capture essential binding patterns typically reserved for structural modeling. By eliminating the reliance on 3D structures, DuaDeep-SeqAffinity provides a highly scalable and efficient solution for high-throughput screening of vast sequence libraries, significantly accelerating the therapeutic discovery pipeline.</p>
            </section>

            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>